KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Common Equity (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Common Equity for 17 consecutive years, with $7.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 47.03% year-over-year to $7.9 billion, compared with a TTM value of $7.9 billion through Dec 2025, up 47.03%, and an annual FY2025 reading of $7.9 billion, up 47.03% over the prior year.
  • Common Equity was $7.9 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $7.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $11.5 billion in Q3 2021 and bottomed at $5.4 billion in Q4 2024.
  • Average Common Equity over 5 years is $8.5 billion, with a median of $8.0 billion recorded in 2023.
  • The sharpest move saw Common Equity tumbled 33.79% in 2024, then soared 47.03% in 2025.
  • Year by year, Common Equity stood at $11.2 billion in 2021, then dropped by 23.53% to $8.6 billion in 2022, then dropped by 5.49% to $8.1 billion in 2023, then plummeted by 33.79% to $5.4 billion in 2024, then soared by 47.03% to $7.9 billion in 2025.
  • Business Quant data shows Common Equity for TEVA at $7.9 billion in Q4 2025, $7.3 billion in Q3 2025, and $6.8 billion in Q2 2025.